Global Parkinson’s Disease Drugs Market is Expected to Witness a CAGR of 7.2% to Reach Revenue of $5,614.6 Million by 2024 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Global
Parkinson’s Disease Drugs Market 2018-2024” report has been
added to ResearchAndMarkets.com’s offering.

Global Parkinson’s Disease Drugs Market is Expected to Witness a CAGR of
7.2% to Reach Revenue of $5,614.6 Million by 2024

Huge patient pool and rising rate of diagnosis are the significant
factors driving the market growth. The Parkinson’s Disease Foundation
has stated that nearly 10 million people are suffering from this
disorder globally. The highest frequency of this disorder is observed in
developed countries, and in the US, almost 60,000 new cases are reported
annually.

PD is an idiopathic disease for which the cause of the occurrence is
still unknown, hence only symptomatic drugs are available in the market
for the treatment. Furthermore, the disorder is diagnosed in the final
stages when the majority of the cells that produce dopamine lose their
functionality. This is demanding more innovative and novel drugs for the
treatment.

Regional Analysis

North America accounts for the largest share of the market, followed by
Europe, Asia Pacific, and Rest of the World. More than 40% of the market
is occupied by Europe, with Germany being the major contributor to the
market growth.

Drug Class Analysis

Based on drug classes, the market is segmented into levodopa, MAO-B
inhibitors, COMT inhibitors, dopamine agonists, anticholinergics, and
others. Levodopa is the most attractive drug in the market owing to its
highly effective treatment in controlling the motor symptoms throughout
the stages of Parkinson’s disease. Recently, in January 2018, Adamas
Pharmaceuticals Inc. launched Gocovri for the treatment of dyskinesia in
individuals with PD, who are taking levodopa. This is the original drug
indicated explicitly for dyskinesia, which is technologically advanced
with the long-term use of levodopa.

Key Players

The major players in the market include Novartis, Roche, AbbVie, Teva
Pharmaceutical, Pfizer, STADA Arzneimittel AG, GSK, Valeant, Merck & Co.
Inc., and Amneal Pharmaceuticals Inc.

Competitive Analysis

New product launch and collaboration are the primary strategies being
followed by the market players to maintain their leadership and
strengthen the market position. In January 2015, Neuropore Therapies
Inc. and UCB S.A. signed a commercialization agreement for NPT200-11.
Recently, Impax Pharmaceuticals’ RYTARY and AbbVie’s DUOPA received the
US FDA approval for the treatment of Parkinson’s disease. Other
strategies include business partnerships, mergers & acquisitions, and a
multifaceted pipeline. Recently, in January 2018, Adamas Pharmaceuticals
Inc. launched Gocovri for the treatment of dyskinesia in individuals
with PD, who are taking levodopa.

Key Topics Covered:

1 Industry Outlook
1.1 Industry Overview
1.1.1
Global Driver for Pharmaceutical Demand:
1.1.2 Pharmaceutical
spending region wise
1.1.3 R&D pipeline in pharmaceutical industry
1.1.4
Top pharma drugs by sales in 2017 ($Million)
1.2 Total Addressable
Market

2 Report Outline
2.1 Report Scope
2.2 Report
Summary
2.3 Research Methodology
2.4 Report Assumptions

3 Market Snapshot
3.1 Market Definition –
Infoholic Research
3.2 Segmented Addressable Market (SAM)
3.3
Trends of Parkinson Diseases Market
3.4 Related Markets
3.4.1
Neurosurgical Devices
3.4.2 Neurointerventional Devices
3.4.3
Over the counter drugs (OTC)

4 Market Outline
4.1 Pipeline Products of
Parkinson Diseases Drugs
4.2 Market Segmentation
4.3 Porter
5(Five) Forces
4.4 PEST Analysis

5 Market Characteristics
5.1 Market Dynamics of
Parkinson Diseases Market
5.1.1 Drivers
5.1.1.1 Increasing
Aging Population
5.1.1.2 Increasing Prevalence of Parkinson Diseases
5.1.2
Opportunities
5.1.2.1 Supportive initiatives from government and
other organizations
5.1.2.2 Exhaustive Pipeline and Increasing
Clinical Trials
5.1.3 Restraints
5.1.3.1 Expiry of patents for
blockbuster drugs and availability of generic drugs
5.1.3.2 Complex
drug development process
5.1.4 DRO – Impact Analysis
5.1.5 Key
Stakeholders

6 Drug Type: Market Size and Analysis
6.1 Overview
6.2
Levodopa
6.3 Dopamine agonists
6.4 MAO-B inhibitors
6.5
COMT Inhibitor
6.6 Anticholinergics
6.7 Others

7 Regions: Market Size and Analysis

8 Competitive Landscape

9 Vendor Profiles
9.1 Novartis AG
9.2
GlaxoSmithKline plc
9.3 F.Hoffmann-La Roche Ltd.
9.4 AbbVie
Inc.
9.5 Merck & Co., Inc.
9.6 Teva Pharmaceutical
Industries Ltd.
9.7 Valeant Pharmaceuticals International Inc.

10 Companies to Watch For
10.1 Boehringer
Ingelheim GmbH
10.2 Amneal Pharmaceuticals, Inc.
10.3 Wockhardt
10.4
STADA Arzneimittel AG
10.5 Pfizer Inc.
10.6 Sun Pharmaceuticals

For more information about this report visit https://www.researchandmarkets.com/r/gsygp8

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Central
Nervous System Drugs